Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Leases (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Current Leases for 5 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 9844.44% year-over-year to $3.6 million, compared with a TTM value of $3.6 million through Dec 2025, up 9844.44%, and an annual FY2025 reading of $3.6 million, up 9844.44% over the prior year.
  • Current Leases was $3.6 million for Q4 2025 at Aligos Therapeutics, up from $3.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.6 million in Q4 2025 and bottomed at $4000.0 in Q2 2024.
  • Average Current Leases over 5 years is $1.6 million, with a median of $1.3 million recorded in 2021.
  • The sharpest move saw Current Leases tumbled 99.87% in 2024, then surged 87450.0% in 2025.
  • Year by year, Current Leases stood at $2.8 million in 2021, then plummeted by 96.1% to $108000.0 in 2022, then surged by 2889.81% to $3.2 million in 2023, then crashed by 98.89% to $36000.0 in 2024, then soared by 9844.44% to $3.6 million in 2025.
  • Business Quant data shows Current Leases for ALGS at $3.6 million in Q4 2025, $3.5 million in Q3 2025, and $3.5 million in Q2 2025.